Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Insilico Medicine reported encouraging Phase 1 results for AI-designed cancer drug ISM6331 in heavily pretreated mesothelioma. * Results presented at ESMO 2026 in Madrid showed tumor shrinkage and disease control, with some responses ongoing at the data cutoff. * No dose-limiting toxicities were reported; treatment-related side effects were mostly mild or moderate, with none leading to discontinuation. * The company plans to complete dose selection before potentially initiating a Phase 2a randomized dose-optimization study in mesothelioma. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260900PR_NEWS_USPR_____CN80710) on October 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.